GP KFPs / SAQs · cardiovascular-health
Stable ischaemic heart disease and angina — KFP-style written assessment
KFP-style staged scenarios on stable IHD: applying the three-feature pain taxonomy and choosing first-line investigation, sequencing the anti-anginal ladder safely around nitrates and PDE5 inhibitors, applying COURAGE/ISCHEMIA to a revascularisation conversation, secondary prevention with PCSK9 escalation, and safety-netting the crescendo presentation.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
Stable IHD: classify the pain, scan proportionately, treat the foundation — COURAGE and ISCHEMIA in the consulting room
KFP 1 (10 marks)
A 61-year-old man presents with three months of central chest tightness on climbing his driveway hill, easing within five minutes of rest. Episodes occur two or three times weekly. He smokes 10/day, takes amlodipine for hypertension, and his father had bypass surgery at 60. Resting ECG is normal. [7] [9]
- Classify his pain using the three-feature taxonomy. (2) [7]
- What is your first-line investigation and why? (4) [9]
- His CTCA shows a proximal LAD stenosis of intermediate severity. Name the functional assessment options that follow. (4) [10]
Model answers
- Typical angina — all three features present (substernal character, exertional provocation, rest relief). Typical pain carries the highest pre-test probability in a 61-year-old male smoker. [7]
- CT coronary angiography — ANZ/NICE first-line for typical/atypical pain with intermediate probability; high negative predictive value; SCOT-HEART showed CTCA reclassified the coronary diagnosis in 27% of patients at 6 weeks versus 1% with standard care. His normal resting ECG excludes nothing. [9]
- Functional confirmation before revascularisation decisions: CT fractional flow reserve on the existing scan, stress echocardiography or myocardial perfusion scintigraphy, or invasive FFR at angiography — FAME 2 showed only functionally significant stenoses (FFR 0.80 or less) carried urgent-revascularisation risk that PCI reduced (composite 4.3% vs 12.7%). [10]
References15ShowHide
- [1]Maron DJ, Hochman JS, Reynolds HR, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease N Engl J Med, 2020.PMID 32227755
- [2]Bangalore S, Maron DJ, O'Brien SM, et al. Management of Coronary Disease in Patients with Advanced Kidney Disease N Engl J Med, 2020.PMID 32227756
- [3]Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease N Engl J Med, 2007.PMID 17387127
- [4]Weintraub WS, Spertus JA, Kolm P, et al. Effect of PCI on quality of life in patients with stable coronary disease N Engl J Med, 2008.PMID 18703470
- [5]Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease N Engl J Med, 2017.PMID 28304224
- [6]Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome N Engl J Med, 2018.PMID 30403574
- [7]Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes Eur Heart J, 2020.PMID 31504439
- [8]Douglas PS, Hoffmann U, Patel MR, et al. Outcomes of anatomical versus functional testing for coronary artery disease N Engl J Med, 2015.PMID 25773919
- [9]SCOT-HEART investigators CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): an open-label, parallel-group, multicentre trial Lancet, 2015.PMID 25788230
- [10]De Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease N Engl J Med, 2012.PMID 22924638
- [11]Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet, 2009.PMID 19482214
- [12]Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial JAMA, 2007.PMID 17456819
- [13]IONA Study Group Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial Lancet, 2002.PMID 11965271
- [14]Long L, Anderson L, Dewhirst AM, et al. Exercise-based cardiac rehabilitation for adults with stable angina Cochrane Database Syst Rev, 2018.PMID 29394453
- [15]Long L, Anderson L, He J, et al. Exercise-based cardiac rehabilitation for stable angina: systematic review and meta-analysis Open Heart, 2019.PMID 31245012